The effect of neoadjuvant therapy on pd-l1 expression and cd8+lymphocyte density in non-small cell lung cancer

HIGHLIGHTS

• who: Philipp Zens from the exhaustion The combination of immune checkpoint blockade and chemotherapy seems to be beneficial especially in patients with low levels of PD-, expressing tumor cells and ongoing trials are reporting positive results of this regimen in patients with resectable lung cancer6, . However, the selection of appropriate patients is currently based only on PD-, expression in tumor tissue prior to medication, which is a suboptimal biomarker. More selective tools or, conceivably, a combination of multiple tumor immunity markers such as tumor mutational burden or , + tumor infiltrating lymphocytes (TILs) are needed to predict response to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.